Usefulness of methotrexate in relapsing idiopathic retroperitoneal fibrosis
Authors' conclusion
In selected patients with RPF who are intolerant or refractory to steroid single therapy, MTX may be considered as useful and safe second-line treatment.
Study context
- Population
- Patients with idiopathic retroperitoneal fibrosis (RPF) receiving second-line methotrexate (MTX), January 2011 to December 2019
- Participants
- 15 patients
- Outcome
- Response to MTX
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
MTX
93%
14 of 15
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Relapse | MTX 2 events |
- Relapse: one on MTX therapy (28 months), the other 58 months after MTX was interrupted
Safety
| Outcome | Values |
|---|---|
| Liver toxicity grade 2Resolved with temporary dosage reduction | MTX 2 events |
| Discontinuation of MTX because of nauseaStopped autonomously | MTX 1 events |
Severe infections
- No severe infections were recorded
Original publication
Usefulness of methotrexate in relapsing idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol. Published 29 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →